Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Separately, HC Wainwright ...

A collaborative study published on January 21 in Nature Communications presents a novel strategy to improve the effectiveness ...

Moderate to severe obstructive sleep apnea was associated with significantly higher odds of having neovascular age-related ...

Oncology, titled "Tumor Metastasis: Mechanistic Insights and Therapeutic Intervention," a research team from Guangzhou ...

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Aymarans, who live in the Andes mountain range of western South America, have evolved their own unique adaptation to life at ...

Researchers have debunked key beliefs about addiction, like that a person must hit "rock bottom" before having treatment or ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Following an injury, such as a traumatic crush injury, the peripheral nervous system is itself often able to effectively ...

Whole-body hypothermia within hours of birth failed to improve outcomes in preterm infants less than 36 weeks' gestational ...